What role for inactivated poliovirus vaccine in the eradication endgame?

Journal of Infectious Diseases

Volumn 193, Issue 10, 2006, Pages 1341-1343

  Kew, Olen ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; INACTIVATED VIRUS VACCINE; ORAL POLIOMYELITIS VACCINE; POLIOMYELITIS VACCINE; VIRUS RNA;

DEVELOPED COUNTRY; DOSE RESPONSE; DRUG FORMULATION; EDITORIAL; ERADICATION THERAPY; HUMAN; INFECTION RISK; POLIOMYELITIS; POLIOMYELITIS VIRUS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; UNITED STATES; VACCINATION; VACCINE DERIVED POLIOMYELITIS VIRUS; VIRUS REPLICATION; VIRUS TRANSMISSION; WORLD HEALTH ORGANIZATION;

HUMANS; IMMUNIZATION PROGRAMS; POLIOMYELITIS; POLIOVIRUS VACCINE, INACTIVATED; POLIOVIRUS VACCINE, ORAL; WORLD HEALTH;

EID: 33646375181     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/503373     Document Type: Editorial

References (25)

1. Oshinsky DM. Polio: an American story. New York: Oxford University Press, 2005.
2. Pan American Health Organization. Director announces campaign to eradicate poliomyelitis from the Americas by 1990. Bull Pan Am Health Organ 1985; 19:213-5.
3. World Health Assembly. Polio eradication by the year 2000. Geneva: World Health Organization, 1988.
4. World Health Organization. Transmission of wild poliovirus type 2-apparent global interruption. Wkly Epidemiol Rec 2001; 76:95-7.
5. Centers for Disease Control and Prevention. Resurgence of wild poliovirus type 1 transmission and effect of importation into polio-free countries, 2002-2005. MMWR Morb Mortal Wkly Rep 2006; 55:145-50.
6. Kew OM, Sutter RW, de Gourville EM, Dowdle WR, Pallansch MA. Vaccine-derived polioviruses and the endgame strategy for global polio eradication. Annu Rev Microbiol 2005; 59:587-635.
7. Prevots DR, Burr RK, Sutter RW, Murphy TV, Advisory Committee on Immunization Practices. Poliomyelitis prevention in the United States: updated recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2000; 49:1-22.
8. Centers for Disease Control and Prevention. Poliovirus infections in four unvaccinated children-Minnesota, August-October 2005. MMWR Morb Mortal Wkly Rep 2005; 54:1053-5.
9. Centers for Disease Control and Prevention. Laboratory surveillance for wild and vaccine-derived polioviruses, January 2004-June 2005. MMWR Morb Mortal Wkly Rep 2005; 54:958-61.
10. Aylward RB, Sutter RW, Heymann DL. OPV cessation-the final step to a "polio-free" world. Science 2005; 310:625-6.
11. Hull HF, Minor PD. When can we stop using oral poliovirus vaccine? J Infect Dis 2005; 192:2033-5.
12. Minor PD, Dunn G. The effect of sequences in the 5′ non-coding region on the replication of polioviruses in the human gut. J Gen Virol 1988; 69:1091-6.
13. Bouchard MJ, Lam DH, Racaniello VR. Determinants of attenuation and temperature sensitivity in the type 1 poliovirus Sabin strain. J Virol 1995; 69:4972-8.
14. Minor PD, Almond JW. Poliovirus vaccines: molecular biology and immune response. In: Semler BL, Wimmer E, eds. Molecular biology of picornaviruses. Washington, DC: ASM Press, 2002:381-90.
15. Centers for Disease Control and Prevention. Poliomyelitis prevention in the United States: introduction of a sequential vaccination schedule of inactivated poliovirus vaccine followed by oral poliovirus vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 1997; 46:1-25.
16. Ogra PL, Faden HS, Abraham R, Duffy LC, Sun M, Minor PD. Effect of prior immunity on the shedding of virulent revertant virus in feces after oral immunization with live attenuated poliovirus vaccines. J Infect Dis 1991; 164:191-4.
17. Abraham R, Minor P, Dunn G, Modlin JF, Ogra PL. Shedding of virulent poliovirus revertants during immunization with oral poliovirus vaccine after prior immunization with inactivated polio vaccine. J Infect Dis 1993; 168:1105-9.
18. Murdin AD, Barreto L, Plotkin S. Inactivated poliovirus vaccine: past and present experience. Vaccine 1996; 14:735-46.
19. Minor PD, Dunn G, Ramsay ME, Brown D. Effect of different immunisation schedules on the excretion and reversion of oral poliovaccine strains. J Med Virol 2005; 75:153-60.
20. Alexander LN, Seward JF, Santibanez TA, et al. Vaccine policy changes and epidemiology of poliomyelitis in the United States. JAMA 2004; 292:1696-701.
21. World Health Organization. Introduction of inactivated poliovirus vaccine into oral poliovirus vaccine-using countries. Wkly Epidemiol Rec 2003; 78:241-50.
22. Laassri M, Lottenbach K, Belshe R, et al. Effect of different vaccination schedules on excretion of oral poliovirus vaccine strains. J Infect Dis 2005; 192:2092-8.
23. WHO Collaborative Study Group on Oral and Inactivated Poliovirus Vaccines. Combined immunization of infants with oral and inactivated poliovirus vaccines: results of a randomized trial in The Gambia, Oman, and Thailand. J Infect Dis 1997;175(Suppl 1):S215-27.
24. Agol VI, Chumakov K, Ehrenfeld E, Wimmer E. Don't drop current vaccine until we have new ones [comment]. Nature 2005;435:881.
25. Sabin AB. Oral poliovirus vaccine: history of its development and use, and current strategies to eliminate poliomyelitis from the world. J Infect Dis 1985; 151:420-36.